Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 1,090 INR
Change Today +17.60 / 1.64%
Volume 661.8K
As of 7:06 AM 05/5/15 All times are local (Market data is delayed by at least 15 minutes).

strides arcolab ltd (STR) Snapshot

Open
1,073
Previous Close
1,072
Day High
1,100
Day Low
1,055
52 Week High
04/8/15 - 1,249
52 Week Low
05/12/14 - 417.62
Market Cap
65.0B
Average Volume 10 Days
769.9K
EPS TTM
--
Shares Outstanding
59.6M
EX-Date
10/16/14
P/E TM
--
Dividend
5.00
Dividend Yield
10.09%
Current Stock Chart for STRIDES ARCOLAB LTD (STR)

Related News

No related news articles were found.

strides arcolab ltd (STR) Related Businessweek News

View More BusinessWeek News

strides arcolab ltd (STR) Details

Strides Arcolab Limited, a pharmaceutical company, develops, manufactures, and sells pharmaceutical products in India and internationally. The company develops generic pharmaceutical product portfolio in therapeutic segments, such as immune-suppressants, anti-virals, antibiotics, complex vitamins, and anti-lipidemics; and offers general tablets, hard and soft gelatin capsules, sachets, potent drugs, liquid filled hard gel capsules, creams, ointments, and liquids and syrups. In addition, it provides branded generic products; supplies drugs in the anti-retroviral and anti-malaria segments; and is engaged in bio generics business, as well as offers and oncology, nephrology, critical care products. The company was formerly known as Strides Pharmaceuticals Private Limited and changed its name to Strides Arcolab Limited in 1996. Strides Arcolab Limited was founded in 1990 and is headquartered in Bengaluru, India.

1,500 Employees
Last Reported Date: 08/14/14
Founded in 1990

strides arcolab ltd (STR) Top Compensated Officers

Founder, Executive Vice Chairman, Managing Di...
Total Annual Compensation: 53.9M
Compensation as of Fiscal Year 2014.

strides arcolab ltd (STR) Key Developments

Strides Arcolab Ltd. Receives ANDA Approval from United States Food & Drug Administration for Polyethylene Glycol 3350, Sodium Chloride, Sodium Bicarbonate and Potassium Chloride for Oral Solution

Strides Arcolab Ltd. announced that it has received approval from the United States Food & Drug Administration for Polythene Glycol 3350, Sodium Chloride, Sodium Bicarbonate, and Potassium Chloride for Oral Solution, 420 grams/11.2 grams/5.72 grams/1.48 grams/4 Liters. The product will be manufactured at the company's Oral dosage facility at Bangalore and marketed by Strides in the U.S. market.

Strides Arcolab Launches Sofosbuvir in India Under the Brand Name Virso

Strides Arcolab has launched a generic drug Sofosbuvir in India under the brand name 'Virso'. In September 2014, Strides entered into a licensing agreement with Gilead Sciences Inc. to bring Hepatitis C cure to 91 developing countries. The product will be available to Indian patients shortly. Sofosbuvir is the first-in-class NS5B polymerase inhibitor to be launched in India for Hepatitis C treatment and represents a paradigm shift in the existing Hepatitis C management. The high potency, high barrier to resistance, pan genotypic activity, once-daily dosage, good safety profile and the limited drug-drug interactions of Sofosbuvir makes it a breakthrough drug in Hepatitis C treatment. This drug in combination therapy has shown to have high cure rates of around 90%. The launch in other markets is subject to approvals from the regulatory authorities in respective countries.

Strides Arcolab Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Strides Arcolab Limited reported earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the company reported net profit after tax of INR 973.99 million or INR 16.29 per diluted share compared to INR 35.25 billion or INR 595.12 per diluted share for the same quarter ended December 31, 2013. Total income from operations was INR 2.42 billion compared to INR 2.53 billion for the same quarter ended December 31, 2013. For the nine months, net profit after tax was INR 4.63 billion or INR 77.38 per diluted share compared to INR 35.61 billion or INR 599.85 per diluted share for the same period ended December 31, 2013. Total income from operations was INR 6.59 billion compared to INR 8.07 billion for the same period ended December 31, 2013.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
STR:IN 1,090.05 INR +17.60

STR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,451 GBp -10.50
Endo International PLC $84.87 USD -1.44
Johnson & Johnson $99.91 USD -0.44
Merck & Co Inc $60.47 USD -0.1709
Pfizer Inc $34.23 USD -0.09
View Industry Companies
 

Industry Analysis

STR

Industry Average

Valuation STR Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow 3.8x
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact STRIDES ARCOLAB LTD, please visit www.stridesarco.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.